Tag Archives: metabolic liver disease

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The rising interest in GLP‑1 MASLD MASH treatment has transformed how clinicians view metabolic therapies for patients with type 2 diabetes and obesity. While GLP‑1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic …

Early in training, many clinicians learn the classic “eye–kidney–foot” framework for recognizing and managing complications of diabetes. However, as science advances, the range of recognized consequences of diabetes—and opportunities for earlier intervention—continues to broaden. Today, the concept of diabetes complications screening must evolve to include conditions such as metabolic dysfunction–associated …